Alteration in antibody-mediated immunity in patients with rituximab-combined chemotherapy and incidence of herpes zoster

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 1, 2010, Pages 99-102

  Ito, Kaori ^a   Okamoto, Masataka ^a   Maruyama, Fumio ^a   Handa, Kosuke ^a   Yamamoto, Yukiya ^a   Watanabe, Masato ^a   Tsuzuki, Motohiro ^a   Mizuta, Shuichi ^a   Kumazawa, Satomi ^a   Ohta, Hideki ^a   Nakano, Itsuko ^a   Emi, Nobuhiko ^a  

^a FUJITA HEALTH UNIVERSITY HOSPITAL   (Japan)

Author keywords

Herpes zoster; Rituximab combined therapy; Serum immunoglobulin G (IgG) level

Indexed keywords

IMMUNOGLOBULIN G; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION CONTROL; MAJOR CLINICAL STUDY; VIRUS REACTIVATION;

EID: 79960813514     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Niitsu N, Okamoto M, Aoki S, et al: Multicenter phase II study of the CyclOBEAP (CHOP-like+etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Ann Hematol 85(6): 374-380, 2006.
2. Romaguera JE. Fayad L, Rodriguez MA, et al: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23: 7013-7023, 2005.
3. Davis TA, Grillo-Lopez AJ, White CA, et al: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgikin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18: 3135-3143, 2000.
4. Sercan A, Hakan H, Saadettin K, et al: Rituximab-related viral infections in lymphoma patiens. Leuk Lymphoma 48(7): 1307-1312, 2007.
5. Virgolini L and Marzocchi V: Rituximab in autoimmune diseases. Biomed Pharmacother 58: 299-309, 2004.
6. Cambridge G, Leandro MJ, Edwards JC, et al: Se-Rologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48: 2146, 2003.
7. Vallerskog T, Gunnarsson I, Widhe M, et al: Treatment with Rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 62: 122, 2007.
8. Popa C, Leandro MJ, Cambridge G, et al: Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology 46: 636, 2007.
9. Genovese M, Emery P, Ruderman E, et al: Immunoglobulin levels and infection rates in patients with rheumatoid arthritis (RA) treated with repeated courses of rituximab. Arthritis Rheum 56: S149, 2007.
10. Bearden CM, Agarwal A, Book BK, et al: Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bakteriophage phoX174. Am J Transplant 5: 50, 2005.
11. Gonzalez-Stawinski GV, Yu PB, Love SD, et al: Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol 98: 175, 2001.
12. Maruyama F, Ezaki K, Okamoto M, et al: A study of toxicities and complications observed in alternating non-cross-resistant chemotherapy (CAMBO-VIP) for non-hodgkin's lymphoma. Gan To Kagaku Ryoho 20(9): 1195-1201, 1993. (Pubitemid 23280718)
13. Tokunaga M, Saito K, Kawabata D, et al: Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66: 470, 2007.
14. Tokunaga M, Fujii K, Saito K, et al: Down-regulation of CD40 and CD80 on B cells in patiens with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 44: 176, 2005.
15. Tanaka Y: B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases. Intern Med 46: 1313, 2007.